万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格:
T25
T-47D/T-47D细胞系/T-47D细胞株/T-47D人乳腺管癌细胞
Cell line name T-47D
Synonyms T-47-D; T47-D; T47D:A; T47D
Accession CVCL_0553
Resource Identification Initiative To cite this cell line use: T-47D (RRID:CVCL_0553)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: JWGray breast cancer cell line panel.
Part of: ICBP43 breast cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Part of: NCI-7 clinical proteomics reference material cell line panel.
Population: Caucasian.
Doubling time: 1.6 days (PubMed=9671407); 59.7 hours, 33.8 hours (Note=With 17-beta-estradiol) (PubMed=32576280); 49.2 hours (PubMed=8562478; PubMed=9815641); 32 hours (CLS=300353); ~30-40 hours (DSMZ=ACC-739); 45.5 hours (NCI-DTP=T-47D); ~43 hours (PBCF); 55.80 hours (JWGray panel).
Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=23671654; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: Glycoproteome analysis by proteomics.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: T470; Cosmic=877451; Cosmic=1152529.
Misspelling: T74D; Cosmic=1027050.
Misspelling: T-47D-RU; Cosmic=1175835.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)
PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)
PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B
Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J.J., Larsson C.
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Genes Chromosomes Cancer 28:308-317(2000)
PubMed=11044355; DOI=10.1054/bjoc.2000.1458; PMCID=PMC2408781
Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C., Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Molecular cytogenetic analysis of breast cancer cell lines.
Br. J. Cancer 83:1309-1317(2000)
PubMed=11343771; DOI=10.1016/S0165-4608(00)00387-3
Rummukainen J., Kytola S., Karhu R., Farnebo F., Larsson C., Isola J.J.
Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.
Cancer Genet. Cytogenet. 126:1-7(2001)
PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)
PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)
PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注:由博辉生物科技(广州)有限公司提供; *发表【英文论文】请标注:From Bohui Biological Technology (Guangzhou) Co., Ltd.
Use of three-dimensional collagen gels to study mechanotransduction in t47d breast epithelial cells
of in vitro models to understand how both biophysical and biochemical signals regulate complex cellular behaviors. T47D breast epithelial cells will differentiate into duct-like tubules when cultured in a floating three-dimensional (3D) collagen gel
细胞治疗是细胞和基因治疗的重要组成部分,它通过使用特定类型的细胞来修复、替换或调节受损的组织和器官。在细胞治疗中,不同类型的细胞因其独特的生物学特性而被广泛应用于多种疾病的治疗。以下是一些常用的细胞类型及其在细胞治疗中的应用。 (1)免疫细胞 免疫细胞是细胞治疗中最重要且研究最多的细胞类型之一,主要包括 T 细胞、自然杀伤细胞(NK 细胞)和树突状细胞(DC 细胞)。 T 细胞:T 细胞是人体免疫系统的核心细胞,具有强大的抗肿瘤能力。CAR-T 细胞疗法是目前最成功的免疫细胞治疗技术
简介 细胞增殖/细胞毒性测定是涉及培养细胞的研究中最常用的测试之一。 其是检查用于治疗的药物浓度的基本初步测试,也是确定各种研究领域(如肿瘤学和细胞死亡)药物疗效和安全性的非常重要的测试。 传统上,WST-8 或 ATP 检测(使用代谢活性作为指标)和 BrdU 或胸腺嘧啶核苷检测(使用 DNA 合成水平作为指标)已用于细胞生长特性的定量评估。 尽管这些检测由于其简易性和吞吐量而对我们有益,但这些检测都是间接评估方法,因此结果可能与实际细胞数无关。 在许多情况下,这些检测是终点评估,有时会
技术资料





